1. Novo Nordisk shares have dropped ~50% since June 2024 due to poor trial results and other negative catalysts. 2. Despite strong market share and promising early results for Amycretin, competition from Eli Lilly and regulatory risks pose significant challenges. 3. NVO's undiversified product pipeline and political risks, including the Inflation Reduction Act, amplify concerns compared to more diversified competitors.